Pivanex

Research use only, not for human use.

Pivanex is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.

Pivanex is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.(In Vitro):In K562 cells, Pivanex (100-500 μM) exhibits significant anti-proliferation activity and enhances apoptosis and caspase activity. Pivanex (200 μM) induces enhancement in the G2-M phase, a moderate enhancement in the S phase, and a slight reduction in G0-G1 of the cell cycle.(In Vivo):Pivanex(200 mg/kg, b.i.d, daily) treatment marked delays in the end stage of disease as defined by the onset of body mass loss by 94.9%. Pivanex(200 mg/kg, b.i.d, daily) obviously improves the survival of SMN7 SMA mice by 84.6%.

AN-9; Pivalyloxymethyl butyrate

Apoptosis

Apoptosis

GSK-3α; GSK-3β

——

——

122110-53-6

202.3

C10H18O4

>98% (HPLC)

——

CCCC(=O)OCOC(=O)C(C)(C)C

——

(-20℃)

With Ice Pack

≥ 2 years